GlobeNewswire

Xceedance Announces Global Availability of MGA Agility Suite

Share

U.K. MGA Archipelago Risk Services adopts the next-generation offering to sell and service its personal lines coverages and package policies

BOSTON, May 06, 2019 (GLOBE NEWSWIRE) -- Xceedance, a global provider of insurance consulting, managed services, technology, data sciences, and blockchain solutions, today announced the availability and client implementation of a new software and services offering, the MGA Agility Suite.

The Xceedance MGA Agility Suite enables established and startup program administrators, managing general agents (MGAs), and managing general underwriters (MGUs) worldwide to swiftly deploy a tailored, advisor-driven sales and service engine to capture profitable market segments — a key competitive differentiator in managing diverse insurance products, especially lower-margin classes of business.

Additionally, Xceedance announced a successful implementation of the MGA Agility Suite for Archipelago Risk Services (Archipelago), helping the London-based MGA to boost underwriting efficiency and augment the policyholder experience.

“The Xceedance MGA Agility Suite provides software and associated services to support MGAs in insurance markets worldwide,” said Travis MacMillian, chief business officer at Xceedance. “MGA operations typically rely on software or platforms intended for primary insurers. In contrast, the dedicated MGA Agility Suite comprises an insurtech platform, coupled with lifecycle services for program administrators, MGAs, and MGUs.”

Through advanced software development and integration with a diverse set of technologies that support operational efficiency, the MGA Agility Suite gives MGAs and their retail agents proficient automation for personalized, intermediated policyholder services. The MGA Agility Suite combines policy-administration capabilities, an underwriting platform, distribution and communication tools, and the business intelligence (BI)/reporting functionality MGAs need to write more business efficiently and profitably. The MGA Agility Suite facilitates regulatory compliance and partnerships with organizations such as actuaries and third-party administrators (TPAs); and it enables robust integration with insurance data providers, payment gateways, general ledger applications, and document generation services. The platform can be hosted on the cloud for superior performance in managing diverse insurance products and core MGA/MGU operations.

“The MGA Agility Suite elevates our personalized service delivery to program administrators, especially with an innovative broker and underwriter portal, and a configurable rating/pricing engine,” said MacMillian. “The automated workflows and streamlined policy lifecycle processes built into the MGA Agility Suite create transactional efficiencies, while enhancing user experience and customer-centricity for MGAs and MGUs."

Archipelago recently deployed the MGA Agility Suite, providing the company with a single platform for clients — via intermediaries — to purchase motor (auto), home, investment property, travel, and pet insurance, quickly and efficiently. In implementing the bespoke platform, Archipelago leveraged operational expertise from five principal insurance capabilities at Xceedance: technology and core systems; actuarial services; insurance data sciences; catastrophe and exposure management; and BI and reporting.

“The Xceedance MGA Agility Suite empowers us with highly-automated workflows and a streamlined policy lifecycle — boosting organizational efficiency, enhancing the policy buying experience, and lowering operating costs,” said Richard Coleman, managing director at Archipelago Risk Services.

About Xceedance
Xceedance is a global provider of strategic consulting and managed services, technology, data sciences, and blockchain to insurance organizations. Domiciled in Bermuda, with offices in the United States, United Kingdom, Germany, Poland, India, and Australia, Xceedance helps insurers launch new products, drive operations, implement intelligent technology and blockchain solutions, deploy advanced analytic capabilities, and achieve business process optimization. The experienced insurance professionals at Xceedance enable re/insurers, brokers, and program administrators worldwide to enhance policyholder service, enter new markets, boost workflow productivity, and improve profitability. For more information, please visit www.xceedance.com.

Media Contact:
Jennifer Overhulse
St. Nick Media Services
(859) 803-6597
jen@stnickmedia.com 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPress release

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPressemelding

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Nexstim reports good initial results on the use of Smartfocus® technology in treatment of major depressive disorder20.8.2019 09:00:00 CESTPress release

Press Release, Helsinki, 20 August 2019 at 10.00 am (EET) Nexstim reports good initial results on the use of Smartfocus ® technology in treatment of major depressive disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD) – announces that the first white paper about the initial experiences of its NBT® system with SmartFocus® technology in treatment of MDD has been published. The white paper is published by Island Psychiatry PC, a New York -based TMS therapy provider and Nexstim. It reports the experiences in the first 10 consecutive patients completing treatment of MDD with Nexstim NBT® system at Island Psychiatry’s clinic. The treatment outcomes of these 10 adult patients were good. 50 % of the patients were in remission at the end of the treatment while 70 % had obtained a clinical response rate. These patient-reported outcomes are hi

SERSTECH AB: Half-year report 1 January – 30 June 201920.8.2019 08:45:00 CESTPress release

SALES INCREASE BY 200% FROM HIGHER MARKET ACCEPTANCE Second quarter 2019 Period 1 January - 30 June 2019 • Net sales: KSEK 5 089 (1 558, +227%) • Net sales: KSEK 8 340 (2 768, +201%) • Profit for the period: KSEK -3 349 (-2 166) • Profit for the period KSEK -7 008 (-5 599) • Earnings per share SEK -0,05 (-0,03) • Earnings per share: SEK -0,11 (-0,09) During Q2, we passed another set of important milestones on our way to becoming a significant player in the security industry and a more mature, professional organization. Our net sales numbers continued to move in the right direction, +227% compared to Q2 2018, and we received significant orders, expanded the reach of our sales network and signed another OEM agreement. We dramatically expanded our R&D capabilities and added dedicated roles for product management and quality assurance, both of which are imperative as our volumes continue to increase. Our operative cash flow continues to improve and for the first half of the year our operat

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso20.8.2019 08:00:00 CESTPress release

Metso Corporation, Stock exchange release on August 20, 2019, at 9:00 a.m. EEST Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the holding of mutual funds managed by BlackRock, Inc. of the total amount of shares and financial instruments entitling to shares of Metso. On August 16, 2019, BlackRock Inc.'s direct holding in Metso shares and in financial instruments entitling to shares fell below the 5 percent threshold. On August 14, 2019, BlackRock, Inc.'s total position in Metso amounted to less than 5 percent of Metso’s shares and votes. Metso’s total number of shares and votes is 150,348,256. BlackRock, Inc.’s holdings according to the notification: % of shares and voting rights (A) % of shares and voting rights through financial instruments (B) Total of both in % (A + B) Res

Intention to list & Company Description20.8.2019 08:00:00 CESTPress release

GG St. Kongensgade 100 og 106 P/S Nasdaq First North, Copenhagen, Bond Market Ticker: GGSTK; ISIN: DK0030444401 For release: 20 August 2019 Intention to list the company’s floating rate (7%) secured bond loan 2019/2020 and company description The Director of GG St. Kongensgade 100 og 106 P/S announces that the Company intends to list its floating rate 7% secured bond loan 2019/2020 for trading on Nasdaq First North, Copenhagen. In connection with this, the Company has prepared a Company Description which has been approved by Nasdaq Copenhagen A/S. A copy of the Company Description accompanies this release and it may also be downloaded from the Investor Relations section of the Company’s website at www.gefiongroup.com The Company anticipates the first day of trading in its Bonds being 23 August 2019. GG St. Kongensgade 100 og 106 P/S, incorporated under the laws of Denmark with business registration number 38 30 68 47, having its registered office at c/o Gefion Group A/S, Østergade 1, 2